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INTRODUCTION 
Parkinson’s disease (PD) is a chronic progressive disorder character-
ized by slowness of movement (bradykinesia), rigidity, tremor, and gait 
abnormalities [1,2]. The loss of dopamine (DA) and its pathway have 
been studied as the crucial neurobiological substrate of motor features in 
PD [3]. According to the previous studies, the imbalance in multiple 
neurotransmitter pathways might lead to deficits in central motor drive 
and, it leads to aberrant recruitment of muscle fibers [4]. These central 
imbalances destabilize can cause the neuromuscular junction and, in-
duce raising muscle fiber alteration with a sarcopenic-like phenotype [5].
Movement difficulties lead to decreased physical activity levels and 
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PURPOSE: This study aimed to investigate the level of physical function, lower body strength, and muscle activation during various 
types of muscle contraction in participants with and without Parkinson’s disease (PD).
METHODS: Twelve participants with PD (mean age=63.17±6.24 years) and 12 age- and sex-matched healthy adults (mean age = 
58.67±6.39 years) were recruited. An isokinetic dynamometer was used to measure the length- and velocity-dependent maximum 
voluntary force and the rate of torque development (RTD) of the knee extensor muscles. Muscle activation of the vastus lateralis (VL), 
vastus medialis (VM), and rectus femoris (RF) muscles of both legs was examined using surface electromyography. The 6-minute walk 
test, chair stand test, timed up-and-go test, sit-and-reach test, and back-scratch test were performed to assess physical function.
RESULTS: Compared to healthy individuals, participants with PD showed significantly lower maximum voluntary force and RTD 
(p<.05), performed fewer repetitions in the chair stand test (11.64±1.75 vs. 17.08±2.27, p<.001), were slower in the timed up-and-
go test (8.36±1.42 vs. 5.65±1.07, p<.001), and walked shorter distances in the 6-minute walk test (424.17±65.97 vs. 539.47±63.18, 
p<.001). However, activation of the three different muscles during isometric and isokinetic muscle contraction was not different 
between participants with and without PD.
CONCLUSIONS: Preserved muscle activation and significantly lower muscle strength during various types of muscle contractions may 
suggest lower muscle strength and efficiency. The lower physical function seen in participants with mild PD could be due to disease and 
low physical activity-related muscle atrophy rather than lower muscle activation.
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impaired strength and physical function in patients with PD [6]. Patients 
with PD have difficulties in activities of daily living, especially due to 
muscle weakness [7]. Muscle weakness may lead to postural instability 
and difficulties in ambulation [8] and can be a secondary cause for bra-
dykinesia in patients with PD [9]. Furthermore, lower extremity muscle 
strength is significantly correlated with clinical severity and the number 
of falls [10]. Falling is a serious problem experienced by a majority (68%) 
of patients with PD [11]. According to Allen et al. [12], patients with PD 
who have low muscle power are 6 times more likely to report multiple 
falls than those who have high muscle power.
Patients with PD's muscle weakness seem to be accompanied by al-
tered voluntary muscle activation [4], increased muscle co-activation and 
stiffness [13], and decreased rate of force development [14]. Furthermore, 
muscular weakness tends to exacerbate as the disease progresses [15], 
and therefore, patients with PD should be monitored constantly. Neuro-
muscular evaluation is important to assess performance-limiting factors, 
the effects of rehabilitation programs, and training intervention that 
limits the symptoms of the pathology [16].
Decreased muscle strength has been observed in patients with PD us-
ing an electromechanical dynamometer. Stevens-Lapsley et al. [4] mea-
sured the weakness, activation deficits, and fatigue in the quadriceps 
muscles of patients with PD and observed that patients with higher dis-
ease severity (Unified Parkinson’s Disease Rating Scale [UPDRS] motor 
score ≥ 31.7) had significantly more quadriceps weakness and central ac-
tivation deficits than those with lower disease severity (UPDRS motor 
score < 31.7) or healthy controls. Durmus et al. [10] tested lower extremi-
ty isokinetic muscle strength in patients with PD and reported a signifi-
cant decrease in isokinetic muscle strength, especially in the hip and 
knee f lexors and extensors. In a study by Inkster et al. [17], reduced 
strength of the hip muscles (hip extensors) contributed to the difficulty 
experienced in standing up from a chair in patients with PD.
Parkinson’s disease is a senile neurological disease caused by a lack of 
dopamine, in which the neuromuscular system and body functions de-
crease at the same time. However, limited studies have been conducted 
to assess neuromuscular characteristics of PD-related pathologic mecha-
nisms and physical functions related to walking, standing up from a 
chair, and daily activities in patients with PD. Furthermore, limited 
studies have reported on muscle function and its relationship with physi-
cal function in patients with PD, such as muscle weakness, loss of ability 
to generate force, and general reconditioning, including electromyogra-
phy (EMG) findings. Therefore, the purpose of the current study is to 
investigate the level of physical function, lower body strength, and mus-
cle activation during various types of muscle contraction in participants 
with and without PD.
METHODS 
1. Participants 
A total of 12 participants with PD (4 males and 8 females; mean 
age = 63.17 years) and age- and sex-matched 12 healthy controls (3 males 
and 9 females; mean age =58.67 years) were recruited. Participants with 
PD were included if they 1) were > 40 years old, 2) scored between 0 and 
3 on the Hoehn and Yahr scale [18], 3) had no known injuries that might 
interfere with motor function, and 4) could walk independently without 
the aid of walking sticks. The control group included healthy partici-
pants who had no known neurological disorders or musculoskeletal in-
juries that might interfere with walking. This study was approved by the 
institutional review board at the Y University (IRB approval number: 
201409-HRBR-234-03). All program administration and outcome evalu-
ations were conducted after receiving written consents. Participants were 
provided with an explanation about the purpose of the study and proce-
dures, and any questions that arose were answered. Participants were in-
formed that they could withdraw from participation whenever they 
wanted. All participants signed an informed consent form before partici-
pating in the study. 
2. Anthropometric measurements
Body weight and body composition including muscle mass, fat mass, 
and fat percentage were measured using bioelectrical impedance analysis 
(Inbody 720, Biospace, Korea). 
3. Maximum voluntary contraction (MVC)
MVC of the knee extensor muscles and joint angle were measured us-
ing an isokinetic dynamometer (Con-Trex MJ, Physiomed, Switzerland). 
The participants’ knee joints were aligned with the axis of the dyna-
mometer and the trunk was secured using velcro straps across the waist 
and chest to prevent excessive movements. For all measurements, partic-
ipants were seated with a hip joint angle of 80°. Maximum isometric 
contractions were performed at 60° knee flexion (0°= full knee exten-
sion). At this joint configuration, participants performed maximum iso-
metric knee extension in two different ways: ballistic (ISO60Ball) (exert 
maximal torque as fast as possible) and ramp (ISO60Ramp) (gradually 
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build up to maximal torque over 3 seconds). In the isokinetic concentric 
trials, knee extension was performed over the range of 0°-110° knee flex-
ion and at angular speeds of 30°/s (CON30) and 120°/s (CON120). 
During isometric and isokinetic contraction strength testing, partici-
pants were instructed to exert maximal voluntary knee extensions 
against the lever arm of the dynamometer. Strong verbal encouragement 
was given, and visual feedback about their torque was provided to pro-
vide motivation and consistency. A rest period of at least 2 minutes was 
given between each trial. Before each isometric and isokinetic concentric 
trials, participants performed familiarization trials with 70%–80% of 
MVC. None of the participants reported fatigue during the familiariza-
tion trials. The participants performed 2 repetitions of isometric ballistic 
(ISO60Ball) and ramp (ISO60Ramp) knee extension contraction and 3 
repetitions of isokinetic knee extension at a velocity of 30°/s (CON30) 
and 120°/s (CON120) for both legs.
Peak torque of the isometric trial was determined by taking the high-
est torque value obtained during the 500-ms plateau phases. The rate of 
torque development (RTD) was derived as the slope of the linear portion 
of torque–time curve. RTD was determined from the first derivative of 
the ascending portion of the torque–time curve and quantified from the 
linear slope of the torque–time curve at time intervals of 0–100 ms [19]. 
Muscle activation was measured using surface EMG electrodes (Tri-
gno wireless EMG, DELSYS, Boston, MA) to assess the vastus lateralis 
(VL), vastus medialis (VM), and rectus femoris (RF) muscles on both 
legs, as described by the SENIAM conventions (www.seniam.org). To re-
duce skin impedance, the skin locations where the electrodes were 
placed were shaved (if necessary), cleaned with ethanol cotton pads, and 
dried. EMG signals were amplified, band-pass filtered (20-450 Hz), and 
digitized with a sampling frequency of 1 kHz using an analog-to-digital 
converter (NI 6036E, National Instruments, Austin, USA). The EMG 
and torque signals were sampled at 1 kHz and stored on a hard drive. 
The signals were analyzed using Chart v 5.5 for windows (AD instru-
ments Ltd, USA). The average of the root-mean-square (RMS) values 
were calculated for the VL, VM, and RF muscles during MVCs test. 
EMG signals of testing contraction were normalized to those of the ref-
erence isometric knee flexion at 60°.
4. Physical function
The 6-minutes walk test, chair stand test, timed up-and-go (TUG) 
test, sit-and-reach test, and back-scratch test were used to measure physi-
cal function [20,21]. For the 6-minutes walk test, participants were asked 
to walk as quickly as possible and cover the furthest distance possible in 
6 min while walking. The distance covered was recorded in meters. For 
the chair stand test, participants were asked to stand up to a full stand-
ing position and then sit as many times as possible in 30 seconds with-
out using arm support. For the TUG test, participants stood up from a 
chair, walked 3 m, turned, returned to the chair, and sat down. The total 
time to completion was recorded to the nearest tenth of a second. For 
the sit-and-reach test, participants were instructed to sit close enough to 
the edge of the chair to be able to straighten one leg and the distance be-
tween extended fingers and the tip of their toe was recorded to the near-
est half of 1 cm. For the back-scratch test, participants were asked to 
bend one hand over the shoulder and the other hand on the middle of 
the back, with the fingers pointing toward each other, trying to make 
them overlap. The distance between the fingertips was recorded to the 
nearest half of 1 cm.
5. Statistical analysis 
All data were analyzed using SPSS 21.0 software (SPSS Inc., Chicago, 
IL, USA) and values were expressed as the mean ± standard deviation 
(SD). The normality for continuous variables was determined by the 
Shapiro–Wilk test. Characteristics of the study participants were com-
pared using the independent t-test for continuous outcomes, including 
age, weight, body mass index (BMI), muscle mass, fat mass, and fat per-
centage, and the chi-square test for categorical outcomes. Since the age 
of the participants with PD and the healthy control group was not simi-
lar, data analysis was performed by controlling for age and sex. Compar-
isons of muscle function and physical function between participants 
with PD and healthy controls were assessed using analysis of covariance 
(ANCOVA) after controlling for age and sex. p-values of < .05 were con-
sidered statistically significant. In addition, Spearman’s correlation and 
partial correlation analyses were used to determine the potential associa-
tions between muscle function and physical function tests.
RESULTS 
1. Characteristics of participants
A total of 24 participants (12 participants with PD and 12 healthy 
controls) participated in this study. The age and anthropometric charac-
teristics of participants are described in Table 1. There was no significant 
difference in sex, age, weight, BMI, muscle mass, fat mass, fat percentage, 
and systolic and diastolic blood pressure between participants with and 
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without PD. 
2.  Comparisons of muscle function and electromyography 
findings between participants with and without 
Parkinson’s disease 
Figs. 1-3 show the comparisons of RTD and peak torque between par-
ticipants with PD and healthy controls, respectively. RTD was signifi-
cantly different between participants with PD and healthy controls (left 
side 3.94 ± 2.57 vs. 9.52 ± 5.02, p=.003; right side 4.66 ± 3.14 vs. 10.64 ±
6.40, p=.015). Participants with PD had lower MVC torque value during 
isometric ballistic contraction (left side: 69.84 ± 27.99 vs. 123.78 ± 47.87, 
p=.004; right side: 74.56 ± 39.39 vs. 128.71 ± 41.07, p=.001), ramp con-
traction (left side: 68.22 ± 24.33 vs. 104.20 ± 41.41, p=.016; right side: 
72.80 ± 35.13 vs. 110.74 ± 39.85, p=.012), and isokinetic contraction (left 
side at a velocity of 30°/s: 66.43 ± 29.12 vs. 101.80 ± 42.18, p=.018; right 
side at a velocity of 30°/s: 70.58 ± 35.03 vs. 99.23 ± 33.98, p=.029; left side 
at a velocity of 120°/s 49.69 ± 22.64 vs. 75.15 ± 32.62, p=.010; right side at 
a velocity of 120°/s 55.35 ± 27.92 vs. 81.88 ± 33.26, p=.025) than healthy 
controls. 
A comparison of the normalized RMS EMG values for various con-
tractions between participants with Parkinson’s disease and healthy 
controls did not reveal any differences, except for the VM in the right 
side isometric ballistic test at 60° (p< .02) (Table 2). 
Table 1. Participant characteristics
Participants with PD (n=12) Healthy controls (n=12)
p-value
Mean SD Mean SD
Sex (male %) 4 (33.3) 3 (25.0) .653
Age (yr) 63.17 6.24 58.67 6.39 .095
Weight (kg) 60.37 9.41 62.66 9.84 .566
BMI 23.56 2.41 24.94 2.54 .874
Muscle mass (kg) 23.76 5.68 24.11 5.00 .437
Fat mass (kg) 16.82 7.08 18.62 3.44 .185
Percent fat (%) 27.83 10.43 29.88 4.16 .537
Disease duration (yr) 8.6 5.86 NA NA NA
Hoehn and Yahr Scale (%) 1 6 (50) NA NA NA
2 6 (50) NA NA NA
BMI, Body mass index; NA, not applicable; PD, Parkinson’s disease.
Significance at p<.05.
Fig. 1. Comparisons of the rate of torque development measured at 60-



























Fig. 2. Comparisons of peak torque achieved during ballistic (BALL MVIC) 
and ramp (RAMP MVIC) isometric contraction between participants with 
PD and healthy adults (Isometric measurements).
p=.004
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Fig. 3. Comparisons of peak torque obtained during slow (30 deg/s) and 
fast (120 deg/s) maximum concentric knee extension between partici-
pants with PD and healthy adults (Isokinetic measurements).
p=.018 p=.029 p=.010 p=.025
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3.  Comparisons of physical function between participants 
with and without Parkinson’s disease 
Table 3 shows the differences in f lexibility and results of the chair 
stand test, the TUG test, and the 6-minute walk test between participants 
with and without PD. After adjusting for age and sex, participants with 
PD performed significantly worse than healthy controls on all physical 
function tests, except for flexibility. Compared to healthy controls, partic-
ipants with PD performed fewer repetitions on the chair stand test (11.64
±1.75 vs. 17.08 ± 2.27, p< .001), were slower on the TUG test (8.36 ±1.42 
vs. 5.65 ±1.07, p< .001), and walked shorter distances on the 6-min walk 
test (424.17± 65.97 vs. 539.47± 63.18, p< .001). No significant differences in 
f lexibility were found between participants with and without PD.
Table 2. Comparison of electromyography findings between patients with Parkinson’s disease and healthy controls
Participants with PD (n=12) Healthy controls (n=12)
p-value
Mean SD Mean SD
EMG (%)
VL
CON30 (L) 166.59 91.63 145.26 38.21 .226
CON30 (R) 158.47 69.12 133.16 53.79 .367
CON120 (L) 193.51 96.50 167.39 50.50 .062
CON120 (R) 169.85 55.42 180.97 75.72 .811
ISO60Ball (L) 104.10 20.40 119.39 28.71 .204
ISO60Ball (R) 106.12 23.12 122.99 32.97 .102
VM
CON30 (L) 153.93 59.03 149.83 55.55 .755
CON30 (R) 142.68 34.18 142.39 59.54 .839
CON120 (L) 181.87 64.74 174.68 68.69 .476
CON120 (R) 176.48 51.07 196.77 92.95 .592
ISO60Ball (L) 106.30 41.12 114.55 34.63 .495
ISO60Ball (R) 94.76 18.12 121.51 35.68 .020*
RF
CON30 (L) 167.45 67.54 163.58 63.02 .590
CON30 (R) 141.30 39.31 132.89 49.56 .418
CON120 (L) 210.74 104.88 179.56 59.50 .101
CON120 (R) 154.47 46.41 148.47 46.75 .566
ISO60Ball (L) 105.88 22.77 120.86 28.01 .154
ISO60Ball (R) 100.56 21.08 109.65 29.24 .279
Adjusted for age and sex.
EMG, electromyography; VL, vastus lateralis; VM, vastus medialis; RF, rectus femoris; CON30, isokinetic knee extension at 30˚/s; CON120, isokinetic knee ex-
tension at 120˚/s; ISO60Ball, ballistic isometric knee extension at 60˚; PD, Parkinson’s disease.
*p<.05.
Table 3. Comparison of functional fitness between participants with and without PD
Participants with PD (n=12) Healthy controls (n=12)
p-value
Mean SD Mean SD
Flexibility (cm)
Sit & reach (L) 6.33 8.67 12.96 8.33 .255
Sit & reach (R) 5.67 8.46 12.79 8.86 .197
Back stretch (L) -14.42 6.46 -12.21 10.74 .803
Back stretch (R) -7.92 9.13 -5.38 11.28 .637
Chair stand (n) 11.64 1.75 17.08 2.27 <.001**
Timed up-and-go (s) 8.36 1.42 5.65 1.07 <.001**
6-min walk (m) 424.17 65.97 539.47 63.18 <.001**
Adjusted age and sex.      
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4.  Association between muscle function and physical 
function
The results of the 6-minute walk test, the chair stand test, and the 
TUG test were associated with muscle function (Table 4). The results of 
the 6-minute walk test were associated with RTD and peak torque on 
ISO60Ball, ISO60Ramp, CON30, and CON120 on both legs, even after 
adjusting for age, sex, and weight. The chair stand test, a measure of low-
er muscle strength, showed a significant correlation with all muscle 
function parameters. However, the correlations failed to reach statistical 
significance after adjusting for age, sex, and weight. The TUG test, a 
measure of speed, agility, and balance, showed significant correlations 
with the rate of force development and peak torque of ISO60Ball on 
both legs, even after adjusting for age, sex, and weight. 
DISCUSSION 
This study investigated the neuro-muscular characteristics and physi-
cal function of participants with PD and compared them with those of 
age- and sex-matched healthy controls. The study results clearly demon-
strate that, as hypothesized, participants with PD had significantly lower 
physical function. Coincide with the reduction in physical function, rate 
of torque development, peak torque during isometric and isokinetic con-
traction were all significantly decreased in participants with PD. Howev-
er, muscle activation, measured by EMG were preserved among partici-
pants with PD. Since muscle strength could be determined by neural 
and muscular alteration due to PD, we can speculate that lower physical 
function observed among our participants were due to lower muscular 
alteration rather than neural factors. However, the reduced rate of torque 
development may suggest a contribution of the central nervous system 
(CNS) for reduced physical function and lower body strength in partici-
pants with PD.  
This result is somewhat contradictory to a recently reported study 
which showed preserved skeletal muscle mass and force expression with 
significant reduction in neuromuscular activation among physically ac-
tive participants with PD. Both studies reported a reduction in the rate 
of torque development in participants with PD, while different results 
were shown in maximum voluntary force: Our study showed signifi-
cantly decreased maximum voluntary force in participants with PD 
while Martignon et al. showed no difference in maximal voluntary force 
between participants with and without PD [22]. Knowing that partici-
pants in the Martignon et al.’s study were physically active, who regularly 
exercise at the University affiliated hospital training center under the su-
pervision of the certified therapist, discrepancy between two studies 
could be due to exercise participation.   
Significantly reduced lower limb muscle strength in participants with 
PD compared to that in healthy controls as observed in our study is not 
surprising. Muscle weakness, which is a reduction in the amount of force 
caused by muscle contraction, has been previously reported in partici-
pants with PD [23]. Furthermore, muscle weakness has been investigated 
in overall muscle groups, including the trunk [24], upper limbs [7], and 
Table 4. Relationships between muscle function and functional fitness tests
6-min walk test Chair stand test Timed up-and-go test
Model 1 Model 2 Model 3 Model 1 Model 2 Model 3 Model 1 Model 2 Model 3
RTD ISO60Ball (L) 0.621** 0.588** 0.535* 0.660** 0.482* 0.437 -.0718** -0.583** -0.583**
RTD ISO60Ball (R) 0.673** 0.605** 0.528* 0.752** 0.559* 0.510* -0.719** -0.525* -0.533*
ISO60Ball (L) 0.566** 0.547* 0.459* 0.601** 0.525* 0.471* -0.632** -0.547* -0.558*
ISO60Ball (R) 0.649** 0.598** 0.507* 0.557** 0.602** 0.558* -0.611** -0.568** -0.598**
ISO60Ramp (L) 0.551** 0.568** 0.453* 0.444* 0.395 0.299 -0.384 -0.401 -0.436
ISO60Ramp (R) 0.714** 0.691** 0.632** 0.609** 0.585** 0.559* -0.489* -0.403 -0.457*
CON30 (L) 0.639** 0.599** 0.506* 0.527** 0.495* 0.431 -0.522** -0.497* -0.519*
CON30 (R) 0.617** 0.654** 0.572** 0.505* 0.620** 0.585** -0.399 -0.41 -0.425
CON120 (L) 0.755** 0.712** 0.648** 0.570** 0.595** 0.550* -0.491* -0.482* -0.502*
CON120 (R) 0.707** 0.567** 0.453* 0.613** 0.475* 0.404 -0.530** -0.344 -0.354
Data are presented as r (correlation coefficient).          
RTD, rate of force development; ISO60Ball, ballistic isometric knee extension at 60˚; ISO60Ramp, ramp isometric knee extension at 60˚; CON30, isokinetic 
knee extension at 30˚/s; CON120, isokinetic knee extension at 120˚/s; L, left; R, right.
Model 1: Crude. Model 2: Partial correlation between muscle function and functional fitness tests after adjusting for age and sex. Model 3: Partial correla-
tion between muscle function and functional fitness tests after adjusting for age, sex, and weight.
*p<.05 (two-tailed); **p<.01 (two-tailed).
https://www.ksep-es.org324 |  Ji-Young Kim, et al.  •  Neuromuscular Characteristics in Participants with PD
Vol.30, No. 3, August 2021: 318-326
lower limbs [10,25] in participants with PD. Our results show that par-
ticipants with PD have lower torque output compared to healthy controls 
despite having similar muscle activation. Clark and Fielding reported a 
significant positive correlation between the rate of surface EMG rise in 
the quadriceps muscle group and power during a leg extension task in 
healthy older adults (r= 0.61, p< .001) [26]. Thus, in our study, results 
showing similar muscle activation in sEMG between participants with 
PD and healthy controls, but significantly weaker muscle strength and 
physical function in participants with PD than in healthy control, was 
rather surprising. Since PD is a central nervous system disorder, identi-
fied as a lower dopamine level, we hypothesized that participants with 
PD will have significantly reduced muscle activation on EMG compared 
with healthy controls. There was no difference in EMG findings between 
participants with PD and healthy controls during MVC, although the 
reason for this is unclear. Time since diagnosis, individual characteris-
tics, or medication use may influence sEMG findings. A possible expla-
nation for this observation in our study would be that the impaired mo-
tor unit recruitment ability might have been compensated by an increase 
in muscle activation of the recruited motor unit, as shown by Stevenson-
Lapsley et al. [4]. In addition, dopaminergic drug administration in pa-
tients with PD modifies their electrophysiological and behavioral pat-
terns, making them more similar to those of normal subjects by restor-
ing the ability of such patients to use more automatic motor learning 
strategies [27]. Since we did not control dopaminergic drugs for the safe-
ty of the participants in this study might explain preserved muscle acti-
vation among our participants. Thus, further research is necessary to 
address this.
This study also shows that participants with PD had significantly low-
er physical function related to daily activities than age- and sex-matched 
healthy controls. In line with findings of previous studies, participants 
with PD in this study also struggled with sitting and standing from a 
chair, walking, and mobility compared to the healthy controls. Such 
functional tasks are physically demanding and required for independent 
living. Canning et al. observed that the participants in the PD group 
walked the lesser distance in the 6-minute walk test than those in the 
control group and that despite recording similar fast-as-possible walking 
velocity, participants in the PD group walked at only 76% of their fast-as-
possible velocity during the 6-min walk test, whereas those in the control 
group walked at 84% of their fast-as-possible velocity [28]. In addition, 
Brod, Mendelsohn, and Roberts have reported that 81% of participants 
with PD have difficulty with standing up from a chair [29].
Previous studies have reported that leg strength, particularly extensor 
strength, is associated with chair-rising performance and functional mo-
bility measured by the TUG test [17,30]. In addition, Falvo and Earhart 
have reported that the 6-min test results are affected in part by disease-
specific characteristics, including age, Hoehn and Yahr scale score, and 
UPDRS score, in participants with PD [31]. However, limited studies 
have been conducted to assess the association between leg strength and 
the 6-min walk test results. In this study, the correlation analysis showed 
that the 6-min walk test result is an adequate indirect marker of muscu-
lar function in participants with PD, even after adjusting for age, sex, 
and weight. Thus, the 6-min walk test is a safe and practical way to mea-
sure muscle fitness in participants with PD. It shows significant correla-
tions with MVC and may be a valuable assessment tool.
Exercise is an effective direct method of treatment, which improves 
muscle strength and physical function in participants with PD. A meta-
analysis has reported that aerobic exercise improves motor actions, bal-
ance, and gait in participants with PD [32]. Progressive resistance exer-
cise also improves muscle size, muscle strength, muscle endurance, and 
neuromuscular function in participants with PD [23]. However, the op-
timal exercise prescription for individuals with PD is yet to be estab-
lished. Hence, it is important to understand the muscular and functional 
characteristics of participants with PD to develop an evidence-based ex-
ercise program for them. Therefore, this study offers important evidence 
that can be used to understand the muscle characteristics of participants 
with PD to develop an evidence-based PD patient-specific exercise-pro-
gram and monitor their progress. 
This study has a few limitations. Because of concerns regarding the 
health of participants with PD, the medication could not be controlled 
during the day of testing. Participants with PD were encouraged to take 
their medication at the regular time on the day of testing. Furthermore, 
because of the physically demanding nature of the tests, participants 
with PD who participated in this study generally had minimally influ-
enced motor function in their lower extremities, with Hoehn and Yahr 
scale scores between 1 and 2, which may limit the generalizability of the 
results to the PD population. Another limitation is younger age among 
participants without PD compared with participants with PD. Although 
this difference is not statistically significant and age was controlled in all 
our analyses, we could not fully eliminate the possibility that better 
physical function among participants without PD observed in our study 
could have been due to their younger age.
https://www.ksep-es.org
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CONCLUSION 
In conclusion, participants with PD had lower muscular function and 
physical function than healthy controls with preserved muscle activa-
tion. Preserved muscle activation yet significantly lower muscle strength 
during various types of muscle contractions may suggest lower muscle 
strength and physical function was seen in participants with mild PD 
could be due to disease and physical activity-related muscle atrophy 
rather than lower muscle activation. Further randomized controlled 
studies are needed to clarify whether exercise training could improve 
muscle strength and physical function of individuals with PD. 
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